Dishman Carbogen

Why is Dishman Carbogen Amcis Ltd falling/rising?

As of 20-Jun, Dishman Carbogen Amcis Ltd's stock price is at 170.80, showing a slight increase but reflecting a significant year-to-date decline of 31.10%. The stock's long-term fundamentals are weak, with poor financial metrics and underperformance compared to market benchmarks.

As of 20-Jun, Dishman Carbogen Amcis Ltd's stock price is currently at 170.80, reflecting a slight increase of 0.3 (0.18%). Despite this recent uptick, the stock has been experiencing a significant decline over various time periods, with a year-to-date drop of 31.10% and a one-year decline of 28.83%. This underperformance is starkly contrasted with the Sensex, which has shown positive returns of 1.69% over the past week and 2.13% over the past month.<BR><BR>Today's performance indicates that the stock has underperformed its sector by 0.25%. Although it has gained for the last two days, resulting in a total increase of 1.87%, it remains below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 28.96% compared to the 5-day average.<BR><BR>Financially, the company has a very attractive valuation with a return on capital employed (ROCE) of 2.6, and it is trading at a discount compared to its peers. However, the long-term fundamentals are weak, as indicated by a low average ROCE of 1.18% and a high debt-to-EBITDA ratio of 5.44 times. The recent negative results, including a 59.4% drop in profit after tax and a high debt-equity ratio of 0.46, further contribute to the stock's struggles.<BR><BR>In summary, while there has been a minor rise in the stock price recently, the overall trend remains downward due to poor long-term growth prospects, weak financial metrics, and significant underperformance compared to market benchmarks.

Which are the latest news on Dishman Carbogen?

What does Dishman Carbogen do?

Dishman Carbogen Amcis Ltd provides Contract Research and Manufacturing Services in the Pharmaceuticals & Biotechnology sector. As of March 2026, it reported net sales of 851 Cr and a net profit of 22 Cr, with a market cap of INR 2,938 Cr.

Overview: <BR>Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History: <BR>The company was incorporated as Carbogen Amcis (India) Limited in 2007 and later changed its name to Dishman Carbogen Amcis Limited on March 27, 2017. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 851 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 22 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 2,938 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.31 <BR>Return on Equity: 1.49% <BR>Price to Book: 0.44 <BR><BR>Contact Details: <BR>Address: Dishman Corporate House, Iscon-Bopal Road Ambli Ahmedabad Gujarat : 380058 <BR>Tel: 91-2717-400102/124 <BR>Email: grievance@dishmangroup.com <BR>Website: htts://imdcal.com

How big is Dishman Carbogen?

As of 10th June, Dishman Carbogen Amcis Ltd has a market capitalization of 2,938.00 Cr, with recent net sales of 2,931.90 Cr and a net profit of 97.45 Cr.

As of 10th June, Dishman Carbogen Amcis Ltd has a market capitalization of 2,938.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,931.90 Cr and a Net Profit of 97.45 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 5,831.52 Cr and Total Assets of 9,986.34 Cr.

Who are in the management team of Dishman Carbogen?

The management team of Dishman Carbogen includes Janmejay R Vyas (Chairman), Deohooti J Vyas (Whole-time Director), Arpit J Vyas (Managing Director & CFO), and several independent directors, along with a Company Secretary. They are responsible for the company's strategic direction and regulatory compliance.

The management team of Dishman Carbogen includes the following members:<BR><BR>1. **Janmejay R Vyas** - Chairman (Non-Executive)<BR>2. **Deohooti J Vyas** - Whole-time Director<BR>3. **Arpit J Vyas** - Managing Director & CFO<BR>4. **Sanjay S Majmudar** - Independent Director<BR>5. **Ashok C Gandhi** - Independent Director<BR>6. **Subir Kumar Das** - Independent Director<BR>7. **Rajendra S Shah** - Independent Director<BR>8. **Shrima Dave** - Company Secretary & Compliance Officer<BR>9. **Maitri K Mehta** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

Who are the peers of the Dishman Carbogen?

Dishman Carbogen's peers include RPG LifeScience, SMS Pharma, Unichem Labs, Aarti Drugs, Panacea Biotec, Novartis India, Solara Active, Morepen Labs, and Kwality Pharma. Dishman Carbogen has the lowest 1-year return at -38.27%, while SMS Pharma leads with 48.87%.

Peers: The peers of Dishman Carbogen are RPG LifeScience, SMS Pharma, Unichem Labs, Aarti Drugs, Panacea Biotec, Novartis India, Solara Active, Morepen Labs, and Kwality Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at RPG LifeScience and Novartis India, while Average management risk is found at SMS Pharma, Unichem Labs, Aarti Drugs, Morepen Labs, and Kwality Pharma, and the rest. Below Average management risk is present at Panacea Biotec and Solara Active. Growth is rated as Good for Unichem Labs and Novartis India, while Below Average growth is seen at RPG LifeScience, SMS Pharma, Aarti Drugs, Panacea Biotec, Solara Active, Dishman Carbogen, Morepen Labs, and Kwality Pharma, and the rest. Capital Structure is rated Excellent for RPG LifeScience, Novartis India, and Morepen Labs, Good for Aarti Drugs and Unichem Labs, and Below Average for SMS Pharma, Panacea Biotec, Solara Active, Dishman Carbogen, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is SMS Pharma at 48.87%, while Dishman Carbogen has the lowest at -38.27%. This shows that Dishman Carbogen's return is significantly lower than its peers. Additionally, the six-month return is negative for Dishman Carbogen, Aarti Drugs, and Solara Active.

Are Dishman Carbogen Amcis Ltd latest results good or bad?

Dishman Carbogen Amcis Ltd's latest Q4 FY26 results show strong revenue growth of 18.85% to ₹851.40 crores, but a concerning 49.55% decline in net profit to ₹21.74 crores, driven by rising costs and a high tax rate. Overall, the results indicate more challenges than positives for the company.

Dishman Carbogen Amcis Ltd's latest results for Q4 FY26 present a mixed picture, with significant concerns overshadowing some positive aspects. On one hand, the company achieved record-high quarterly revenue of ₹851.40 crores, reflecting an impressive year-on-year growth of 18.85%. This indicates strong demand for its services and successful client acquisition.<BR><BR>However, the net profit for the same quarter was ₹21.74 crores, which represents a drastic decline of 49.55% compared to the previous year. This sharp drop in profitability is alarming, particularly as it coincides with a significant increase in employee costs, which rose by over 25% year-on-year. The operating margin also contracted to 19.14%, down from 21.32% a year ago, indicating that while revenues are growing, the company's ability to convert those revenues into profit is deteriorating.<BR><BR>Additionally, the profit after tax margin fell to just 2.55%, down from 6.02% in the same quarter last year, highlighting serious operational challenges. The extraordinarily high tax rate of 52.87% further exacerbated the decline in net profit, raising concerns about the sustainability of the company's business model.<BR><BR>In summary, while Dishman Carbogen's revenue growth is commendable, the significant drop in net profit and ongoing cost pressures suggest that the latest results are more concerning than positive. Investors may need to closely monitor the company's ability to address these challenges moving forward.

Should I buy, sell or hold Dishman Carbogen Amcis Ltd?

When is the next results date for Dishman Carbogen Amcis Ltd?

The next results date for Dishman Carbogen Amcis Ltd is 19 May 2026.

The next results date for Dishman Carbogen Amcis Ltd is scheduled for 19 May 2026.

Is Dishman Carbogen technically bullish or bearish?

As of December 2, 2025, the market trend for Dishman Carbogen has shifted to mildly bearish, indicated by bearish MACD readings and Bollinger Bands on the weekly chart, despite some short-term support from daily moving averages.

As of 2 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, supported by the weekly and monthly MACD readings, both indicating a bearish momentum. The Bollinger Bands show a bearish signal on the weekly chart, while the daily moving averages are mildly bullish, suggesting some short-term support. The KST and OBV are also mildly bearish on the weekly timeframe. Overall, the combination of these indicators points to a bearish sentiment in the current market environment for Dishman Carbogen.

How has been the historical performance of Dishman Carbogen?

Dishman Carbogen's historical performance shows steady growth in net sales from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025, with improved profitability indicators, including a profit after tax of INR 3.24 crore in March 2025. Total liabilities and assets increased, reflecting a stronger financial position, while cash flow from operations remained stable.

Answer:<BR>The historical performance of Dishman Carbogen shows a fluctuating trend in key financial metrics over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Dishman Carbogen's net sales have shown a steady increase from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. The total operating income followed a similar trend, rising from INR 2,140.69 crore in March 2022 to INR 2,711.50 crore in March 2025. However, the total expenditure, excluding depreciation, increased from INR 1,809.32 crore in March 2022 to INR 2,242.56 crore in March 2025, impacting the operating profit, which saw a rise to INR 468.94 crore in March 2025 from INR 331.37 crore in March 2022. Despite this, the profit before tax turned positive at INR 19.31 crore in March 2025 after being negative in the previous years. The profit after tax also improved to INR 3.24 crore in March 2025 from a loss of INR 153.45 crore in March 2024. On the balance sheet, total liabilities increased to INR 9,986.34 crore in March 2025 from INR 8,634.20 crore in March 2022, while total assets rose to INR 9,986.34 crore in March 2025, indicating a growth in the company's financial position. Cash flow from operating activities remained relatively stable, with INR 375 crore in March 2025, while net cash inflow was recorded at INR 76 crore for the same period. Overall, Dishman Carbogen has shown signs of recovery and growth in its financial performance over the past few years.

Is Dishman Carbogen overvalued or undervalued?

As of November 6, 2025, Dishman Carbogen is considered fairly valued with a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72, outperforming the Sensex with a 37.05% return over the past year.

As of 6 November 2025, Dishman Carbogen's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently considered fairly valued. Key ratios include a PE ratio of 28.07, an EV to EBITDA of 10.39, and a Price to Book Value of 0.72. <BR><BR>In comparison to its peers, Dishman Carbogen's PE ratio is lower than that of Sun Pharma, which stands at 35.02, and significantly lower than Divi's Lab at 79.09. However, it is on par with Cipla, which has a PE of 22.27, and Dr. Reddy's Labs at 17.42. Notably, Dishman Carbogen has outperformed the Sensex over the past year with a return of 37.05% compared to the Sensex's 3.65%, reinforcing its current valuation status.

Who are the top shareholders of the Dishman Carbogen?

The top shareholders of Dishman Carbogen include Adimans Technologies LLP with 59.32%, individual investors with 25.31%, and Mukul Mahavir Agrawal holding 5.5%. Additionally, foreign institutional investors hold 9.49%, and mutual funds have a combined stake of 1.06%, with no pledged promoter holdings reported.

The top shareholders of Dishman Carbogen include the promoters, with Adimans Technologies LLP holding the highest stake at 59.32%. Additionally, individual investors collectively own 25.31% of the company. Among public shareholders, Mukul Mahavir Agrawal is notable with a holding of 5.5%. The company also has 61 foreign institutional investors (FIIs) holding 9.49% and 6 mutual fund schemes with a combined holding of 1.06%. There are no pledged promoter holdings reported.

Has Dishman Carbogen declared dividend?

Dishman Carbogen Amcis Ltd has declared a 10% dividend, amounting to ₹0.2 per share, with an ex-date of September 12, 2019. However, there have been no dividends declared since then, resulting in a 0% dividend return across multiple periods despite significant price returns.

Dishman Carbogen Amcis Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.2<BR>- Ex-date: 12 Sep 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -0.48%, the dividend return was 0%, resulting in a total return of -0.48%.<BR><BR>Over the past year, the price return was 85.25%, with a dividend return of 0%, leading to a total return of 85.25%.<BR><BR>In the last 2 years, the price return was 116.96%, while the dividend return remained at 0%, culminating in a total return of 116.96%.<BR><BR>For the 3-year period, the price return was 124.29%, with a dividend return of 0%, resulting in a total return of 124.29%.<BR><BR>In the 4-year period, the price return was 27.47%, and the dividend return was 0%, leading to a total return of 27.47%.<BR><BR>Over the last 5 years, the price return was 273.97%, with a dividend return of 0%, resulting in a total return of 273.97%.<BR><BR>Overall, Dishman Carbogen has declared a dividend in the past, but there have been no dividends declared since then, as indicated by the 0% dividend return across multiple periods. The company has shown significant price returns over the years, particularly in the 5-year period, despite the absence of recent dividends.